Equities Analysts Offer Predictions for GeoVax Labs, Inc.’s Q3 2024 Earnings (NASDAQ:GOVX)

GeoVax Labs, Inc. (NASDAQ:GOVX) – Research analysts at Roth Capital decreased their Q3 2024 EPS estimates for shares of GeoVax Labs in a research note issued on Thursday, August 8th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.35) for the quarter, down from their prior estimate of ($0.47). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for GeoVax Labs’ current full-year earnings is ($7.41) per share. Roth Capital also issued estimates for GeoVax Labs’ Q4 2024 earnings at ($0.90) EPS, FY2024 earnings at ($5.52) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at $0.59 EPS and FY2028 earnings at $16.07 EPS.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.57) by $0.58. The firm had revenue of $0.30 million during the quarter. During the same quarter in the previous year, the business posted ($3.30) earnings per share.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Monday. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Finally, Roth Mkm assumed coverage on shares of GeoVax Labs in a research note on Tuesday, July 16th. They set a “buy” rating and a $20.00 target price on the stock.

GeoVax Labs Stock Up 15.2 %

GOVX stock opened at $2.50 on Monday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $9.75. The firm’s 50-day simple moving average is $2.33 and its 200 day simple moving average is $2.14.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs at the end of the most recent reporting period. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.